Psychometric properties of the itch numeric rating scale in patients with moderate to severe plaque psoriasis using data from a randomized clinical trial

被引：0
|
作者：
Naegli, April [1 ]
Zhu, Baojin [1 ]
Gaich, Carol [1 ]
Heredia, Emily [1 ]
Song, Grace [2 ]
机构：
[1] Eli Lilly & Co, Indianapolis, IN 46285 USA
[2] Macrostat, Shanghai, Peoples R China
来源：
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2014年 / 70卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
P8729
引用
收藏
页码：AB181 / AB181
页数：1
相关论文
共 50 条
  • [11] Topical 0.25% desoximetasone spray efficacy for moderate to severe plaque psoriasis: a randomized clinical trial
    Saleem, Mohammed D.
    Negus, Deborah
    Feldman, Steven R.
    JOURNAL OF DERMATOLOGICAL TREATMENT, 2018, 29 (01) : 32 - 35
  • [12] The safety of efalizumab in patients with moderate to severe plaque psoriasis: Summary of clinical trial experience
    Leonardi, C
    Goffe, B
    Sobell, J
    Caro, I
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2004, 50 (03) : P157 - P157
  • [13] Worst Itch Numeric Rating Scale for Prurigo Nodularis: A Secondary Analysis of 2 Randomized Clinical Trials
    Kwatra, Shawn G.
    Yosipovitch, Gil
    Kim, Brian
    Stander, Sonja
    Rhoten, Stephanie
    Ivanescu, Cristina
    Haeusler, Nadine
    Brookes, Ella
    Msihid, Jerome
    Makhija, Melanie
    Bansal, Ashish
    Thomas, Ryan B.
    Bahloul, Donia
    JAMA DERMATOLOGY, 2024, 160 (08) : 813 - 821
  • [14] Effect of Costimulatory Blockade With Abatacept After Ustekinumab Withdrawal in Patients With Moderate to Severe Plaque Psoriasis The PAUSE Randomized Clinical Trial
    Harris, Kristina M.
    Smilek, Dawn E.
    Byron, Margie
    Lim, Noha
    Barry, William T.
    McNamara, James
    Garcet, Sandra
    Konrad, Robert J.
    Stengelin, Martin
    Bathala, Pradeepthi
    Korman, Neil J.
    Feldman, Steven R.
    Boh, Erin E.
    Barber, Kirk
    Laumann, Anne E.
    Helfrich, Yolanda Rosi
    Krueger, Gerald G.
    Sofen, Howard
    Bissonnette, Robert
    Krueger, James G.
    JAMA DERMATOLOGY, 2021, 157 (11) : 1306 - 1315
  • [15] Ixekizumab for the treatment of the patients with moderate to severe plaque psoriasis: Clinical data from a real-world experience
    Gonulal, Melis
    Altunay, Ilknur Kivanc
    Dogan, Sinan
    Turkmen, Meltem
    Balci, Didem Didar
    Ozturkcan, Serap
    DERMATOLOGIC THERAPY, 2022, 35 (12)
  • [16] Brodalumab provides rapid improvement in psoriasis-related itch and pain in patients with moderate-to-severe plaque psoriasis
    Lebwohl, M.
    Reich, K.
    Paul, C.
    Rosen, M.
    Hansen, K.
    BRITISH JOURNAL OF DERMATOLOGY, 2017, 177 : 75 - 75
  • [17] Patient-reported Outcomes and Clinical Response in Patients with Moderate-to-severe Plaque Psoriasis Treated with Tonsillectomy: A Randomized Controlled Trial
    Thorleifsdottir, Ragna Hlin
    Sigurdardottir, Sigrun Laufey
    Sigurgeirsson, Bardur
    Olafsson, Jon Hjaltalin
    Sigurdsson, Martin Ingi
    Petersen, Hannes
    Gudjonsson, Johann Eli
    Johnston, Andrew
    Valdimarsson, Helgi
    ACTA DERMATO-VENEREOLOGICA, 2017, 97 (03) : 340 - 345
  • [18] Efaluzimab for patients with moderate to severe plaque psoriasis: A randomized controlled trial (vol 290, pg 3073, 2003)
    Gordon, KB
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2004, 291 (09): : 1070 - 1070
  • [19] Validity of a Single Worst Itch Numeric Rating Scale (WI-NRS) Measurement to Identify Patients with Moderate or Severe CKD-Associated Pruritus
    Mccafferty, Kieran
    Schaufler, Thilo
    Morin, Isabelle
    Wen, Warren
    Chan Lili
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2024, 35 (10):
  • [20] The effect of adalimumab on reducing depression symptoms in patients with moderate to severe psoriasis: A randomized clinical trial
    Menter, Alan
    Augustin, Matthias
    Signorovitch, James
    Yu, Andrew P.
    Wu, Eric Q.
    Gupta, Shiraz R.
    Bao, Yanjun
    Mulani, Parvez
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2010, 62 (05) : 812 - 818
12345